817 related articles for article (PubMed ID: 25202087)
21. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
[TBL] [Abstract][Full Text] [Related]
22. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.
Blay JY; Reichardt P
Expert Rev Anticancer Ther; 2009 Jun; 9(6):831-8. PubMed ID: 19496720
[TBL] [Abstract][Full Text] [Related]
23. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
George S; Reichardt P; Lechner T; Li S; Cohen DP; Demetri GD
Ann Oncol; 2012 Dec; 23(12):3180-3187. PubMed ID: 22858558
[TBL] [Abstract][Full Text] [Related]
24. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
Kang YK; Ryu MH; Yoo C; Ryoo BY; Kim HJ; Lee JJ; Nam BH; Ramaiya N; Jagannathan J; Demetri GD
Lancet Oncol; 2013 Nov; 14(12):1175-82. PubMed ID: 24140183
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
26. Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study.
Yeh CN; Wang SY; Tsai CY; Chen YY; Liu CT; Chiang KC; Chen TW; Liu YY; Yeh TS
Int J Surg; 2017 Mar; 39():30-36. PubMed ID: 28110026
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
28. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Montemurro M; Gelderblom H; Bitz U; Schütte J; Blay JY; Joensuu H; Trent J; Bauer S; Rutkowski P; Duffaud F; Pink D
Eur J Cancer; 2013 Mar; 49(5):1027-31. PubMed ID: 23140824
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment--lessons learned.
Cheng CT; Tsai CY; Yeh CN; Chiang KC; Chen YY; Wang SY; Chen TW; Tseng JH; Jung SM; Chen TC; Yeh TS
Anticancer Res; 2014 Nov; 34(11):6617-25. PubMed ID: 25368266
[TBL] [Abstract][Full Text] [Related]
31. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
[TBL] [Abstract][Full Text] [Related]
32. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
33. Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
Rutkowski P; Magnan H; Chou AJ; Benson C
BMC Cancer; 2017 Nov; 17(1):717. PubMed ID: 29110655
[TBL] [Abstract][Full Text] [Related]
34. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
[TBL] [Abstract][Full Text] [Related]
35. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
Ganjoo KN; Villalobos VM; Kamaya A; Fisher GA; Butrynski JE; Morgan JA; Wagner AJ; D'Adamo D; McMillan A; Demetri GD; George S
Ann Oncol; 2014 Jan; 25(1):236-40. PubMed ID: 24356634
[TBL] [Abstract][Full Text] [Related]
36. Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
Lyseng-Williamson KA
BioDrugs; 2013 Oct; 27(5):525-31. PubMed ID: 23975637
[TBL] [Abstract][Full Text] [Related]
37. Gastrointestinal stromal tumors, version 2.2014.
von Mehren M; Randall RL; Benjamin RS; Boles S; Bui MM; Casper ES; Conrad EU; DeLaney TF; Ganjoo KN; George S; Gonzalez RJ; Heslin MJ; Kane JM; Mayerson J; McGarry SV; Meyer C; O'Donnell RJ; Pappo AS; Paz IB; Pfeifer JD; Riedel RF; Schuetze S; Schupak KD; Schwartz HS; Van Tine BA; Wayne JD; Bergman MA; Sundar H
J Natl Compr Canc Netw; 2014 Jun; 12(6):853-62. PubMed ID: 24925196
[TBL] [Abstract][Full Text] [Related]
38. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
Patel S
Cancer Treat Rev; 2012 Aug; 38(5):467-72. PubMed ID: 22035971
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment with sunitinib in a young patient with metastatic gastrointestinal stromal tumor after failure on adjuvant imatinib.
Kapoor R; Khosla D; Kumar P; Kumar N; Bera A
J Cancer Res Ther; 2011; 7(4):491-3. PubMed ID: 22269418
[No Abstract] [Full Text] [Related]
40. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
Demetri GD; Heinrich MC; Fletcher JA; Fletcher CD; Van den Abbeele AD; Corless CL; Antonescu CR; George S; Morgan JA; Chen MH; Bello CL; Huang X; Cohen DP; Baum CM; Maki RG
Clin Cancer Res; 2009 Sep; 15(18):5902-9. PubMed ID: 19737946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
